reports
- Maxime Kogge
BEKB BEKAERT SA
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
SSAB A SSAB AB CLASS A
SZG SALZGITTER AG
VOE VOESTALPINE AG
ACX ACERINOX SA
ERA ERAMET SA
NDA AURUBIS AG
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
RIO RIO TINTO PLC
BHP BHP GROUP LTD
AMAG AMAG AUSTRIA METALL AG
VUL VULCAN ENERGY RESOURCES
AAL ANGLO AMERICAN PLC
- Baptiste Lebacq
- Christophe-Raphaël Ganet
- Emmanuel Matot
- Thomas Zlowodzki
BEKB BEKAERT SA
SLB.N SCHLUMBERGER NV
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
GTT GAZTRANSPORT & TECHNIGAZ SA
SSAB A SSAB AB CLASS A
SZG SALZGITTER AG
VOE VOESTALPINE AG
ACX ACERINOX SA
ERA ERAMET SA
P2F PETROFAC LIMITED
SAVE SAVENCIA SA
TUB TUBACEX S.A.
SOC SUBSEA 7 S.A.
NDA AURUBIS AG
ROYAL VOPAK NV
SBO SCHOELLER-BLECKMANN OILFIELD EQUIPMENT AG
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
IRES IRISH RESIDENTIAL PROPERTIES REIT PLC
TGS TGS-NOPEC GEOPHYSICAL COMPANY ASA
FNTN FREENET AG
TRE TECNICAS REUNIDAS SA
RIO RIO TINTO PLC
TEC TECHNIPFMC PLC
SAE SHOP APOTHEKE EUROPE NV
BHP BHP GROUP LTD
AMAG AMAG AUSTRIA METALL AG
ALHGR HOFFMANN GREEN CEMENT TECHNOLOGIES SA
VK VALLOUREC SA
VUL VULCAN ENERGY RESOURCES
TE TECHNIP ENERGIES NV
SPM SAIPEM S.P.A.
TEN TENARIS S.A.
PLX PLUXEE NV
VIRI VIRIDIEN
LOUP SOCIETE L.D.C.
AAL ANGLO AMERICAN PLC
- Baptiste Lebacq
- Christophe-Raphaël Ganet
- Emmanuel Matot
- Thomas Zlowodzki
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
BEKB BEKAERT SA
SLB.N SCHLUMBERGER NV
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
GTT GAZTRANSPORT & TECHNIGAZ SA
SSAB A SSAB AB CLASS A
FORTUM FORTUM OYJ
SZG SALZGITTER AG
VOE VOESTALPINE AG
ACX ACERINOX SA
GEBN GEBERIT AG
ERA ERAMET SA
P2F PETROFAC LIMITED
TUB TUBACEX S.A.
SOC SUBSEA 7 S.A.
NDA AURUBIS AG
ROYAL VOPAK NV
SBO SCHOELLER-BLECKMANN OILFIELD EQUIPMENT AG
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
TGS TGS-NOPEC GEOPHYSICAL COMPANY ASA
TRE TECNICAS REUNIDAS SA
RIO RIO TINTO PLC
TEC TECHNIPFMC PLC
BHP BHP GROUP LTD
AMAG AMAG AUSTRIA METALL AG
ALC ALCON INC.
VK VALLOUREC SA
VUL VULCAN ENERGY RESOURCES
INPST INPOST S.A.
TE TECHNIP ENERGIES NV
SPM SAIPEM S.P.A.
TEN TENARIS S.A.
VIRI VIRIDIEN
AAL ANGLO AMERICAN PLC
- Maxime Kogge
BEKB BEKAERT SA
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
SSAB A SSAB AB CLASS A
SZG SALZGITTER AG
VOE VOESTALPINE AG
ACX ACERINOX SA
ERA ERAMET SA
NDA AURUBIS AG
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
RIO RIO TINTO PLC
BHP BHP GROUP LTD
AMAG AMAG AUSTRIA METALL AG
VUL VULCAN ENERGY RESOURCES
AAL ANGLO AMERICAN PLC
Bekaert - Update on the Share Buyback Program and Liquidity Agreement
Bekaert - Update on the Share Buyback Program and Liquidity Agreement Update on the Share Buyback Program and the Liquidity Agreement Period from 25 December 2025 to 31 December 2026 Share Buyback ProgramOn , Bekaert announced the start of the next tranche of its share buyback program, for a total maximum consideration of up to € 25 million. As announced previously, the purpose of the Program is to cancel all shares repurchased. Bekaert announces today that during the period from 25 December 2025 to 31 December 2026, Kepler Cheuvreux SA on behalf of Bekaert has bought 26 680 shares. Th...
Bekaert - Update over het Inkoopprogramma van Eigen Aandelen en Liquid...
Bekaert - Update over het Inkoopprogramma van Eigen Aandelen en Liquiditeitsovereenkomst Update over het Inkoopprogramma van Eigen Aandelen en de Liquiditeitsovereenkomst Periode van 25 december 2025 tot 31 december 2026 Inkoopprogramma van Eigen AandelenOp , kondigde Bekaert de start aan van de volgende tranche van haar inkoopprogramma, voor een totaalbedrag van maximaal € 25 miljoen. Zoals eerder aangekondigd heeft het inkoopprogramma tot doel alle ingekochte aandelen te vernietigen. Bekaert kondigt vandaag aan dat gedurende de periode van 25 december 2025 tot 31 december 2026, Kepler ...
- ING Helpdesk
- Hilde Van Boxstael
- Livio Luyten
- Michiel Declercq
- Wim Lewi
Bekaert - Update on the Share Buyback Program and Liquidity Agreement
Bekaert - Update on the Share Buyback Program and Liquidity Agreement Update on the Share Buyback Program and the Liquidity Agreement Period from 18 December 2025 to 24 December 2025 Share Buyback ProgramOn , Bekaert announced the start of the next tranche of its share buyback program, for a total maximum consideration of up to € 25 million. As announced previously, the purpose of the Program is to cancel all shares repurchased. Bekaert announces today that during the period from 18 December 2025 to 24 December 2025, Kepler Cheuvreux SA on behalf of Bekaert has bought 49 066 shares. Th...
Bekaert - Update over het Inkoopprogramma van Eigen Aandelen en Liquid...
Bekaert - Update over het Inkoopprogramma van Eigen Aandelen en Liquiditeitsovereenkomst Update over het Inkoopprogramma van Eigen Aandelen en de Liquiditeitsovereenkomst Periode van 18 december 2025 tot 24 december 2025 Inkoopprogramma van Eigen AandelenOp , kondigde Bekaert de start aan van de volgende tranche van haar inkoopprogramma, voor een totaalbedrag van maximaal € 25 miljoen. Zoals eerder aangekondigd heeft het inkoopprogramma tot doel alle ingekochte aandelen te vernietigen. Bekaert kondigt vandaag aan dat gedurende de periode van 18 december 2025 tot 24 december 2025, Kepler ...
IBA signs contract for a three-room Proteus®PLUS solution to be instal...
IBA signs contract for a three-room Proteus®PLUS solution to be installed at the Seoul St. Mary’s Hospital Louvain-La-Neuve, Belgium, December 26, 2025 – (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a contract with the Catholic University of Korea, Seoul St. Mary’s Hospital, one of the largest hospital in South Korea, for a Proteus®PLUS1 solution to be installed in Seoul. The contract includes the equipment of a Proteus®PL...
IBA signe un contrat pour l’installation d’une solution Proteus®PLUS à...
IBA signe un contrat pour l’installation d’une solution Proteus®PLUS à trois salles au Seoul St. Mary’s Hospital Louvain-la-Neuve, Belgique, le 26 décembre 2025 - IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de protonthérapie pour le traitement du cancer, annonce aujourd’hui la signature d’un contrat avec le Catholic University of Korea, Seoul St. Mary’s Hospital, l’un des plus grands hôpitaux de Corée du Sud, pour l’installation d’une solution Proteus®PLUS1 à Séoul. Le contrat comprend l’éq...
- ING Helpdesk
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Michiel Declercq
- Thibault Leneeuw
- Wim Lewi
Bekaert - Update on the Share Buyback Program and Liquidity Agreement
Bekaert - Update on the Share Buyback Program and Liquidity Agreement Update on the Share Buyback Program and the Liquidity Agreement Period from 11 December 2025 to 17 December 2025 Share Buyback ProgramOn , Bekaert announced the start of the next tranche of its share buyback program, for a total maximum consideration of up to € 25 million. As announced previously, the purpose of the Program is to cancel all shares repurchased. Bekaert announces today that during the period from 11 December 2025 to 17 December 2025, Kepler Cheuvreux SA on behalf of Bekaert has bought 50 000 shares. Th...
Bekaert - Update over het Inkoopprogramma van Eigen Aandelen en Liquid...
Bekaert - Update over het Inkoopprogramma van Eigen Aandelen en Liquiditeitsovereenkomst Update over het Inkoopprogramma van Eigen Aandelen en de Liquiditeitsovereenkomst Periode van 11 december 2025 tot 17 december 2025 Inkoopprogramma van Eigen AandelenOp , kondigde Bekaert de start aan van de volgende tranche van haar inkoopprogramma, voor een totaalbedrag van maximaal € 25 miljoen. Zoals eerder aangekondigd heeft het inkoopprogramma tot doel alle ingekochte aandelen te vernietigen. Bekaert kondigt vandaag aan dat gedurende de periode van 11 december 2025 tot 17 december 2025, Kepler...
Bekaert: Transparency Law
Bekaert: Transparency Law Transparency LawDisclosure in accordance with the Law of 2 May 2007 Pursuant to Articles 15 §1 and 18 §1 of the Law of 2 May 2007 on the disclosure of major holdings in issuers whose shares are admitted to trading on a regulated market, NV Bekaert SA (“Bekaert”) publishes the following information: Status as of 15 December 2025 Basic data Total capital: € 159 782 000.00 Total number of securities conferring voting rights: 51 315 868 shares Total number of voting rights (the denominator): 51 315 868 (one voting right per share) Rea...
Bekaert: Transparantiewetgeving
Bekaert: Transparantiewetgeving TransparantiewetgevingOpenbaarmaking conform de Wet van 2 mei 2007 Conform artikelen 15 §1 en 18 §1 van de Wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen in emittenten waarvan aandelen zijn toegelaten tot de verhandeling op een gereglementeerde markt maakt NV Bekaert SA (“Bekaert”) volgende informatie bekend: Toestand op 15 december 2025 Basisgegevens Totaal kapitaal: € 159 782 000,00 Totaal aantal stemrechtverlenende effecten: 51 315 868 aandelen Totaal aantal stemrechten (de noemer): 51 315 868 (één st...
IBA acquires ORA expanding its strategic leadership in Nuclear Medicin...
IBA acquires ORA expanding its strategic leadership in Nuclear Medicine Louvain-La-Neuve, Belgium, 19 December 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, acquires ORA, a global trailblazer in radiochemistry based in Belgium. This acquisition emphasizes IBA’s long-term commitment to the fast-developing and promising field of nuclear medicine. It reinforces IBA’s position at the forefront of innovation in precision oncology enabling for better diagnostic and more personalized patient...
Avec l’acquisition d’ORA, IBA renforce son leadership stratégique en m...
Avec l’acquisition d’ORA, IBA renforce son leadership stratégique en médecine nucléaire Louvain-la-Neuve, Belgique, le 19 décembre 2025 - IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélération de particules et acteur de premier plan en médecine nucléaire, acquiert ORA, pionnier mondial de la radiochimie, basé en Belgique. Cette acquisition illustre l'engagement à long terme d'IBA dans le domaine en pleine expansion et à fort potentiel de la médecine nucléaire. Elle consolide la position d'IBA à l’avant-garde de l'innovation en oncologie de précision, p...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.